Regarding the therapeutic agents for the rare entity, we have previously found that rigosertib (ON 01910.Na) can inhibit growth of DLBCL by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex and specific knockdown of c-Myb and TRAF6 induced tumor cell apoptosis and cell cycle arrest18. This evidence concerns the gene MYB and diffuse large B-cell lymphoma.